Dyadic Provides Phase 1 Clinical Trial Update for Its Recombinant Protein RBD Vaccine Candidate
Portfolio Pulse from Benzinga Newsdesk
Dyadic has completed dosing of patients for its recombinant protein RBD vaccine candidate, with no major safety concerns or serious adverse events reported. The vaccine produced an immune response at both dose levels. A full study report is expected in Q4, 2023.
July 24, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dyadic's successful completion of Phase 1 dosing for its vaccine candidate without any major safety concerns could boost investor confidence.
The successful completion of Phase 1 dosing without any major safety concerns is a positive development for Dyadic. This could increase investor confidence in the company's ability to develop a successful vaccine, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100